Earnings

An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.

Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.

OTC erectile dysfunction treatment Eroxon has made it to the Nordics through local distributor Navamedic, which has reported strong consumer uptake.

OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.

Herbalife adds distributors and training as sales slow; Amphastar bullish on Primatene Mist $100M full-year target; and ChromaDex net sales up 12%.

Plant-based digestive health remedy Iberogast, alongside Bepanthen Derma and Supradyn dietary supplements, are the brands currently driving sales growth at Bayer Consumer Health, according to the firm's Q2 financial report.

Kenvue maintains full-year guidance after 0.3% Q2 net sales dip beat market expectations. Essential health segment alone drove sales; self-care and skin health/beauty faltered. US sales of Neutrogena Collagen Bank pre-aging platform launched on TikTok shop, a first for the brand.

Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.

OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Haleon has begun reformulating phenylephrine-containing oral decongestants marketed in the US as the company looks to get ahead of an anticipated FDA decision on the ingredient's use in OTC cough and cold products. The UK-based consumer health manufacturer revealed its plan as it reported organic sales up 3.5% in the first half of 2024.

Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.

Strong uptake of its innovative plant-based omega-3 products is helping to drive an increase in dietary supplements sales for ingredients supplier DSM-Firmenich.

P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.

Unilever hopes to double the value of its product innovations this year, ultimately targeting as many as 12 innovations, each costing more than €100m, beginning in 2025, CEO Hein Schumacher says during 25 July earnings presentation.

Nestlé is extending its offer to US patients using GLP-1 drugs like Ozempic and Wegovy for weight-loss with the launch of a dedicated website. Through the site, consumers can purchase a range of Nestlé's dietary supplement products to support their weight loss goals. The website goes live as Nestlé reports its first-half results.

“The game is still totally open,” said Sanofi CFO François-Xavier Roger in response to questions about how the company intends to separate its Consumer Healthcare business. The comments came as Sanofi reported its Q2 results.

Reckitt has designated its Mead Johnson infant nutrition and home care businesses as non-core operations. The company will now reorganize to sharpen its focus on the consumer health and hygiene markets in the pursuit of sustainable, long-term growth.

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2024 results over the coming weeks.

Alliance Pharma has been hit by a non-cash impairment charge of £46.4m related to its Amberen dietary supplement reflecting the brand's struggles in the US e-commerce market.